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Background: We evaluated the performance of various commercial assays for the molecu-
lar detection of human papillomavirus (HPV); the recently developed AdvanSure HPV 
Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV 
PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2).
Methods: All 3 tests were performed on 177 samples, and any sample that showed a dis-
crepancy in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or 
sequencing. On the basis of these results, we obtained a consensus HPV result, and the 
performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection 
by using the 2 real-time PCR assays. 
Results: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays; 
however, the results of the 3 assays with 37 samples were discrepant. Compared with the 
consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Ab-
bott PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively. 
For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and 
Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanS-
ure PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA 
genotyping and/or sequencing.
Conclusions: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and 
the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can si-
multaneously differentiate type 16/18 HPV from other types.
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INTRODUCTION
Persistent infection with oncogenic human papillomavirus (HPV) 
types has been shown to be necessary for the development of 
cervical intraepithelial neoplasia (CIN 1) and cervical cancer. 
Therefore, testing for oncogenic HPV infection could serve as an 
accurate means of detecting women at risk for cervical cancer. 
Moreover, HPV testing would be required as a primary screen-
ing tool in the era of HPV vaccination [1]. Numerous studies 
have established that HPV DNA testing is significantly more 
sensitive than Pap cytology for the detection of high-grade cervi-
cal intraepithelial neoplasia (CIN 2) or worse, and it is recom-
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mended for primary cervical cancer screening and triage of bor-
derline cytological abnormalities [2].
  Since the 1960s, cytology-based screening has led to major 
reductions in the incidence of cervical cancer and related mor-
tality. Due to the increased sensitivity of HPV DNA testing, the 
combined use of cytological testing and HPV DNA testing with 
Hybrid Capture 2 (HC2) (Qiagen, Gaithersburg, MD, USA) in 
screening has been approved by the US Food and Drug Admin-
istration (FDA) for women aged 30 yr and over. For the last de-
cade, the HC2 test has been the most important HPV diagnostic 
assay, and it is still the most frequently used worldwide. In the 
last several years, advances in HPV detection methods have 
been made, and a wide variety of assays are now available [3]. 
The recently developed Abbott RealTime High Risk HPV PCR 
assay is a real-time PCR assay designed to detect not only 14 
high-risk HPV genotypes, but also to simultaneously distinguish 
HPV type 16/18 from other HPV types. The application of this 
assay has yet to be investigated in Korea. LG Life Sciences (Seoul, 
Korea) has also developed a real-time PCR assay (AdvanSure 
HPV Screening real-time PCR), which detects not only 41 HPV 
genotypes, but also simultaneously differentiates HPV type 16/18 
from other HPV types; however, the performance of this assay 
has yet to be investigated.
  We evaluated the performance of the AdvanSure HPV Screen-
ing real-time PCR assay and the Abbott RealTime High Risk HPV 
PCR assay in comparison with the HC2 test using 177 liquid-
based cytology samples for their ability to detect HPVs. 
METHODS
1. Specimens
A total of 177 cytology specimens were obtained from women 
who visited the gynecology clinic at Ewha Womans University 
Mokdong Hospital from July to September 2010. The median 
age of the patients was 42 yr (range, 21-77). Pathological diag-
noses on the basis of cervical cytology and Pap smear results 
were within the normal limits in 127 patients (72%). Atypical 
squamous cells of undetermined significance (ASC-US) were 
observed in 11 (7%), CIN1 in 19 (10%), CIN2 in 7 (4%), CIN3 in 
9 (5%), and invasive carcinoma in 4 patients (2%). A single cer-
vical specimen was collected from all participants using a cyto-
brush and was suspended into Cervical Sampler solution (Qia-
gen) according to the manufacturer’s instructions. 
2. Study design
All specimens were tested using the HC2, AdvanSure PCR, and 
Abbott PCR assays, and samples showing any discordant re-
sults were genotyped using INNO-LiPA HPV Genotyping (Inno-
genetics, Gent, Belgium) and/or sequencing. The samples that 
were negative in all 3 tests were considered negative in the con-
sensus HPV result, and samples that were positive in all 3 tests 
were considered positive in the consensus HPV result. Other 
samples (N=37) with discrepant results in the 3 assays were 
typed by INNO-LiPA genotyping (N=34) and/or sequencing 
(N=11), and the consensus HPV result was determined based 
on the targeted HPV type [4]. For the consensus HPV result of 
any discrepant INNO-LiPA and sequencing results, either the 
INNO-LiPA or sequencing results were used. We calculated the 
sensitivity and specificity of each test based on the consensus 
HPV result. Additionally, in the 2 real-time PCR assays (AdvanS-
ure PCR and Abbott PCR), the results for the detection of HPV 
16/18 were also compared.
  This study was approved by the institutional review boards of 
our institution.
3. Hybrid Capture 2 HPV DNA Test (HC2)
The Hybrid Capture 2 HPV DNA Test (Qiagen) is a sandwich 
capture molecular hybridization assay that provides a semi-
quantitative result through chemiluminescent detection. This 
test can detect 13 high-risk (HR) HPV genotypes (HR: 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). This test was per-
formed according to the manufacturer’s instructions. Specimens 
with relative light unit/cutoff ratios (RLU/CO) ≥1.0 were consid-
ered positive.
4.     AdvanSure HPV Screening real-time PCR assay (AdvanSure 
PCR)
The AdvanSure HPV Screening real-time PCR assay (LG Life 
Sciences) is a real-time PCR assay that detects 41 HPV geno-
types (HR: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 
66, 67, 68, 69, 70, 72, and 73; and low risk (LR): 3, 6, 10, 11, 27, 
32, 34, 40, 42, 43, 44, 54, 55, 57, 61, 62, 71, 74, 81, and 84), and 
also differentiates HPV type 16/18 from other HPV types. In a 
single reaction, this test can detect and distinguish the signals 
for HPV 16/18 from non-16/18 types as well as an internal con-
trol. The test was performed according to the manufacturer’s 
instructions.
5. Abbott RealTime High Risk HPV assay (Abbott PCR) 
The Abbott RealTime High Risk HPV assay (Abbott Molecular, 
Abbott Park, IL, USA) is a real-time PCR assay developed for 
the detection of DNA from 14 high-risk HPV genotypes (HR: 16, Hwang Y, et al.
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18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). HPV 16- 
and HPV 18-specific probes and a probe for human beta-globin 
(internal control) are labeled with different dyes while the other 
HR HPV probes are labeled with the same dye. The test was 
performed according to the manufacturer’s instructions.
6. INNO-LiPA HPV Genotyping (INNO-LiPA) 
The INNO-LiPA HPV Genotyping test (Innogenetics) is a geno-
typing assay based on reverse line-blot hybridization. This test 
allows for the identification of 28 HPV types (HR: 16, 18, 31, 33, 
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69/71, 70, and 73; and 
LR: 6, 11, 34, 40, 42, 43, 44, 54, and 74). Testing was performed 
according to the manufacturer’s instructions.
7. Sequencing
Two primers (MY and GP) were designed using internal frag-
ments of the HPV L1 region (LG Life Sciences, Korea). PCR was 
performed using 10 µL of HS Taq premix (Genet Bio, Korea), 10 
µL of each primer set and 10 µL of extracted template DNA in 
the Takara PCR Thermal Cycler Dice (Takara Bio INC., Japan). 
The PCR mixture was denatured for 5 min at 95°C, which was 
followed by 40 cycles of 15 sec at 95°C, 45 sec at 55°C, and 30 
sec at 74°C for the MY region, or 15 sec at 95°C, 45 sec at 48°C, 
and 30 sec at 74°C for the GP region to amplify the PCR mix-
ture. A final extension step was done at 72°C for 5 min. The PCR 
products were purified using the QIAquick PCR purification kit 
(Qiagen, Germany). Sequencing of positive PCR samples was 
performed by Cosmogenetech Laboratory (Korea), and the DNA 
sequences were aligned with the basic local alignment search 
tool (BLAST) for analysis. 
RESULTS
The sensitivities and specificities of the HC2, AdvanSure PCR, 
and Abbott PCR assays are shown in Table 1. We determined 
the consensus HPV result considering the target HPVs of each 
test and, in discrepant samples, the results of INNO-LiPA and/
or sequencing. Additionally, we evaluated the accuracy of each 
test according to the consensus HPV result. The sensitivities of 
HC2, AdvanSure PCR, and Abbott PCR were 97.6%, 91.7%, and 
86.9%, respectively, and the specificities were 83.9%, 98.8%, 
Table 1. Comparison of the HC2, AdvanSure PCR, and Abbott PCR 
assay results with the consensus HPV results
Consensus HPV results Sensitivity   
(%)
Specificity    
(%) kappa
+ −
HC2 − 82 15 97.6 83.9 0.8088 
− 2* 78
AdvanSure  + 88 1 91.7 98.8 0.8982 
  PCR − 8 80
Abbott PCR + 73 0 86.9 100.0 0.8745 
− 11
† 93
*One sample showed a false-negative result for HPV type 16; 
†Three sam-
ples showed false-negative results for HPV type 16.
Table 2. The discordant results and interpretation of the HC2, AdvanSure PCR, and Abbott PCR assays with 37 samples
N
HC2 AdvanSure PCR Abbott PCR
HPV types
†
Result Interpretation Result Interpretation Result Interpretation
  2 − + − 40, 53
  5 + FP − − negative 
10 + FP + − 43, 44, 53, 61, 69, 70, 71
  1 − FN +* +* 16
  1 − FN + − FN 51
  1 − + FP − 90
  7 + − FN + 51, 52, 56
  1 + − FN − FN 52
  6 + + − FN 31, 39, 45, 52, 68
  1 + +* − FN
‡ 16, 31, 52, 70
  1 + +* + FN
‡ 16, 56
  1 + +* + FN
‡ 16, 52, 56, 59
−, +, and +*, indicate a negative result, a positive result, and a positive result for HPV type 16 and/or 18, respectively; 
†HPV types were determined using 
INNO-LiPA and/or sequencing in 37 discordant samples and the determined types were shown; 
‡Abbott PCR did not detect HPV type 16 in 3 samples.
Abbreviations: FN, false negative; FP, false positive.Hwang Y, et al.
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and 100.0%, respectively. The kappa coefficient between the 
consensus HPV result and HC2, AdvanSure PCR, and Abbott 
PCR were 0.8088, 0.8982, and 0.8745, respectively.
  The discordant results in the HC2, AdvanSure PCR, and Ab-
bott PCR assays are summarized in Table 2. Of the 177 sam-
ples, 140 (79%) showed concordant results in all 3 tests; 75 
samples were positive in all 3 tests, and 65 were negative in all 3 
tests. The remaining 37 samples showed discrepant results 
among the 3 tests. They were subsequently genotyped with 
INNO-LiPA (N=34) and/or sequencing (N=11). 
  According to the HPV types determined by INNO-LiPA and/or 
sequencing, the HC2 assay yielded 15 false-positive and 2 false-
negative results, including 1 false-negative for HPV type 16. The 
AdvanSure PCR assay yielded 1 false-positive and 8 false-nega-
tive results, which included HPV types 51, 52, and 56. The Ab-
bott PCR assay yielded only 11 false-negative results for sam-
ples containing HPV types 16, 31, 52, 56, 59, and 70, including 
3 false-negative HPV type 16 samples. 
  The 2 real-time PCR assays could separately detect oncogenic, 
HR HPV types 16 and/or 18; therefore, performance for the de-
tection of HPV type 16 and/or 18 was compared for these 2 as-
says. Of the 177 samples, 25 samples were AdvanSure PCR (+)/
Abbott PCR (+), 149 samples were AdvanSure PCR (-)/Abbott 
PCR (-), and 3 samples were AdvanSure PCR (+)/Abbott PCR (-). 
The concordance rate was 98.3%, and the kappa coefficient was 
0.9335, which indicated nearly perfect concordance. Among the 
3 discrepant samples, 1 sample was not only negative for types 
other than 16/18 (type 31, 52, and 70) but also negative for type 
16, and the other 2 samples were positive for types other than 
16/18 (type 52, 56, and 59), but negative for type 16 (Table 3).
DISCUSSION
The HC2 test has demonstrated the clinical value of HPV testing 
in most key randomized controlled clinical trials and other clini-
cal trials [5-7]. Recently, it has been recommended that new 
HPV assays show clinical characteristics similar to the HC2 as-
say in the process of clinical validation of high risk-HPV tests 
before they can be used for cervical cancer screening purposes 
[2]. We investigated 2 real-time PCR assays (AdvanSure PCR 
and Abbott PCR) for HPV detection and compared them with 
the HC2 assay. We determined the consensus HPV result based 
on the results of the 3 assays and further genotyping assays for 
discrepant samples [4]. The performance of each assay was 
then compared with the consensus HPV result. In general, the 
evaluation of new tests consists of analytical and clinical perfor-
mance (sensitivity, specificity, and detection limit), and a com-
parison between the new tests and a reference test; however, this 
study was limited to information comparing the 3 tests. There-
fore, further studies are needed.
  In the HC2 assay, the sensitivity was 97.6%, which was higher 
than that of the 2 real-time PCR assays (91.7% and 86.9%). How-
ever, 15 samples showed false-positive results, with a specificity 
of 83.9%, which was lower than the other 2 assays. The false-
positive rate has been reported as 5.6-10.3% [8, 9]. This analyti-
cal inaccuracy has been suggested to be due to the cross-reactiv-
ity of the probe cocktail with untargeted HPV types [8-10]. A next-
generation diagnostic system could resolve these problems [11].
  The recently developed AdvanSure PCR assay is a real-time 
PCR assay designed to detect numerous HPV types (21 HR HPV 
types and 20 LR HPV types) and separately discriminate HPV 
types 16 and/or 18 from other types using an additional probe. 
With the AdvanSure PCR assay, 8.3% of samples (8/96) were 
false negatives, for a sensitivity of 91.7%, which was lower than 
that of the HC2 assay. These samples were genotyped using 
INNO-LiPA and/or sequencing as HPV types 51, 52, and 56. Ac-
cording to the AdvanSure PCR manual, the analytical sensitivi-
ties for these HPV types (10,000-100,000 copies/reaction) were 
relatively lower than that for the other types (1-1,000 copies/re-
action) [12]. The specificity of the AdvanSure PCR assay was 
98.8% and was higher than that of the HC2 assay. The kappa 
coefficient was almost perfect in the 3 tests, but that of the Ad-
vanSure PCR assay (k=0.8982) was higher than that of the 
other 2 tests (0.8088 and 0.8745 for the HC2 and Abbott PCR 
assays, respectively). Although the AdvanSure PCR assay can 
detect most HPV types, it does not differentiate LR HPV from 
HR HPV, and the LR HPV types are too vague to suggest suffi-
cient information to clinicians.
  The Abbott PCR assay is also a real-time PCR assay based 
on concurrent individual genotyping for type 16 and/or type 18 
Table 3. Concordance between the AdvanSure PCR and Abbott PCR 
assays for the detection of type 16 and/or 18 HPV
Abbott PCR
Total kappa
+ −
AdvanSure PCR + 25 3* 28
− 0 149 149 0.9335
Total 25 152 177
*These 3 samples were shown to contain type 16 by INNO-LiPA and/or se-
quencing. One sample, which contained HPV types 16, 31, 52, and 70, 
showed negative results for both HPV 16 and other HPV types, while the 
other 2, which contained HPV types 16, 52, 56, and 59, showed negative 
results for HPV 16 but positive results for other HPV types.Hwang Y, et al.
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and pooled detection of 12 other HR HPVs. In the Abbott PCR 
assay, no samples were false positive, so its specificity (100%) 
was the highest among the 3 assays. However, the sensitivity 
was 86.9%, the lowest among the 3 assays. We genotyped the 
false-negative samples (n=11), which contained HPV types 16, 
51, 52, 56, and 59, and in 3 of the 11 false-negative samples, 
the clinically important HR HPV type 16 was not detected. Ac-
cording to previous studies [13-15], the agreements between 
the Abbott PCR assay and the HC2 assay, which has been FDA-
approved to show scientific reproducibility, were approximately 
93-95%. This false negativity may be due to low viral load and 
multiple infections. There were multiple infections (16, 31, 52, 
56, 59, and 70) in 3 of the false negative samples where the Ab-
bott PCR was positive for other HPVs and negative for HPV 16. 
According to the Abbott PCR assay manual, the analytical sen-
sitivity for these HPV types was 500-2,000 copies/reaction [16]; 
however, we could not determine the viral load of these samples. 
The 2 real time PCR assays utilize a fully automated or semi-au-
tomated platform, so those assays are easier to perform than 
the HC2 assay.
  In conclusion, the recently developed AdvanSure PCR and 
Abbott PCR assays are less sensitive than the HC2 assay, but 
more specific than the HC2 assay for the detection of HPV. The 
overall performance of the 2 real-time PCR assays is compara-
ble to the HC2 assay, and these PCR assays can simultaneously 
differentiate HPV types 16/18 from other HPV types.
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